Skip to main content
ADIM logo

ADIM — Investor Relations & Filings

Ticker · 4142 ISIN · TW0004142005 LEI · 549300M5TV8YGVXU1827 TW Manufacturing
Open in API
Filings indexed 1,804 across all filing types
Latest filing 2018-08-08 Director's Dealing
Country TW Taiwan
Listing TW 4142

About ADIM

http://www.adimmune.com.tw/

ADIMMUNE CORPORATION, established in 1965, specializes in the research, development, and large-scale manufacturing of human vaccines and biologics. The company is a primary supplier of seasonal influenza and tetanus vaccines, maintaining production facilities that adhere to PIC/S GMP, US FDA, and EU standards. Its operations encompass the full product lifecycle, from initial R&D to commercial distribution. In addition to its proprietary vaccine portfolio, the company provides Contract Development and Manufacturing Organization (CDMO) services, supporting collaborative development and global supply chains. Recognized for its technical expertise in viral and bacterial vaccine production, the organization focuses on delivering high-quality immunization solutions to international markets while leveraging its history as a pioneering vaccine laboratory.

Recent filings

Filing Released Lang Actions
107年07月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, supervisors, and senior management, with specific numbers of shares held, pledged shares, and related information. The content focuses on insider shareholdings and their changes, which aligns with disclosures about personal share transactions or holdings by company directors and executives. There is no indication of financial results, meeting materials, or regulatory announcements. The document length is 3815 characters, which is relatively short but contains detailed insider shareholding data. Therefore, the document best fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2018-08-08 Chinese
107年07月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of insiders, including directors, general managers, and their related parties. It shows the number of shares held, changes in holdings, and classifications of shares. There is no indication of financial statements, earnings data, or management discussion. The content is focused on insider shareholdings and transactions. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives. The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2018-08-08 Chinese
公告本公司107年6月份自結財務報表中，高流動性資產及短 期借款等相關資訊
Regulatory Filings Classification · 95% confidence The document is a short announcement (857 characters) from a listed company providing monthly financial data for June 2018 (107/06 in ROC calendar). It includes specific financial figures such as cash, short-term borrowings, and other liquidity-related items. The document references compliance with a Taiwan Stock Exchange regulation and provides a brief explanation of the company's liquidity status. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory disclosure of financial information for a specific month, which fits the category of a Regulatory Filing (RNS) as it is a compliance announcement rather than a full report. The document is not a report publication announcement since it contains actual financial data, but it is not a full financial report either.
2018-07-31 Chinese
107年年報及股東會資料 — 2018_4142_20180627F05.pdf
Annual Report Classification · 100% confidence The document is a detailed record of a shareholders' meeting (股東常會議事錄) held by 國光生物科技股份有限公司, including attendance, voting results, and approval of the company's annual business report and financial statements for the fiscal year 106 (which corresponds to 2017 in the Gregorian calendar). It contains the auditor's report with an unqualified opinion, detailed financial statements (balance sheet, income statement, cash flow, etc.), and management's discussion of business results and outlook. The presence of audited financial statements, auditor's report, and comprehensive business report indicates this is the company's official annual report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2017
2018-07-12 Chinese
107年年報及股東會資料 — 2018_4142_20180627F17.pdf
Major Shareholding Notification Classification · 95% confidence The document contains a table listing the top ten shareholders and their shareholding percentages, along with relationships among them. It is a detailed disclosure of major shareholders and their interrelations, which is typical of a Major Shareholding Notification. The document length is short (1457 characters), and it does not contain financial statements or management discussion, so it is not an Annual Report or Interim Report. It is not an announcement of voting results or a proxy statement. The content is focused on shareholding information, fitting the Major Shareholding Notification category.
2018-07-12 Chinese
107年年報及股東會資料 — 2017_4142_20180627F04.pdf
Annual Report Classification · 100% confidence The document is titled as a 年報 (Annual Report) for the fiscal year 106 (which corresponds to 2017 in the Gregorian calendar) of a company named 國光生物科技股份有限公司. It contains detailed sections typical of an annual report, including a letter to shareholders, company overview, governance report, financial overview, business operations, research and development, and detailed information about directors and management. The document length is substantial (15,000 characters), and it includes comprehensive financial and operational data rather than just an announcement or summary. There is no indication that this is merely a report publication announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2017
2018-07-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.